#Canada #Toronto #Biologics #AmacaThera #AmacaGel

AmacaThera Collaborates with Leading Global Pharmaceutical Company

AmacaThera, a biotechnology firm currently in the clinical stage, has recently announced a strategic partnership with a prominent global pharmaceutical company. This collaboration aims to develop a groundbreaking long-acting biologic that requires only a single injection. The key tool in this endeavor is AmacaThera's advanced hydrogel delivery platform, known as Amacagel™.

Leveraging Advanced Technology

The development initiative will integrate Amacagel™ with the therapeutic modalities of the partnering pharmaceutical company, creating a novel combined approach. This initiative will harness the distinct strengths and resources of both organizations, streamlining the development process of this innovative biologic product. Molly Shoichet, Chief Scientific Officer at AmacaThera, expressed enthusiasm for this collaboration, noting that it allows the company to utilize its robust delivery expertise to succeed in the realm of novel biologics.

The Amacagel™ technology has undergone rigorous testing in conjunction with various therapeutic agents—ranging from small molecules to biologics and stem cells—demonstrating its versatility and effectiveness. This partnership signifies a promising advancement, following the recent successful Phase 1 human trial results involving Amacagel™ used alongside a local anesthetic, which provided valuable human data about the platform’s integration capabilities.

Accelerating Drug Development

Mike Cooke, the CEO of AmacaThera, emphasized that this collaboration builds upon the company’s manufacturing expertise and the human data accumulated through its hydrogel platform. It uniquely positions AmacaThera to create timely and effective solutions, addressing challenges faced in drug injection methods. He highlighted the distinctiveness of their hydrogel technology—despite extensive research on hydrogels in general, AmacaGel™ stands out due to its compatibility with a wide range of drug modalities, an efficient and cost-effective manufacturing process, and substantial real-world human data.

This partnership arose through the Connect-Pharma initiative organized by CQDM, which fosters collaboration between Canadian companies and global pharmaceutical representatives. This endeavor showcases the strong industry confidence in AmacaThera’s innovative platform, as noted by Raphael Hofstein, a board member of CQDM. Mark Steedman, Senior Business Development Director at CQDM, added that the low-risk profile associated with AmacaThera's technology suggests that this project could progress swiftly and yield valuable data in a short timeframe.

About AmacaThera

AmacaThera develops advanced hydrogel formulations aimed at overcoming critical challenges in therapeutic drug delivery. Their flagship product, Amacagel™, is designed to enable the creation of long-lasting therapies that enhance patient outcomes while minimizing systemic side effects. The company is focused on driving innovation in therapeutic areas such as pain management and oncology.

The proprietary Amacagel™ platform comprises a fast-gelling physical hydrogel made from two established polymers. It is formulated to liquefy under shear forces, allowing it to be administered via a conventional syringe, where it then rapidly gels at body temperature to form a depot. AmacaThera's leading product under this platform, AMT-143, showcases its capability as a long-acting, non-opioid local anesthetic aimed at delivering effective postoperative pain relief.

Conclusion

With the ever-evolving landscape of drug delivery and biologics, this partnership marks a significant step forward in the biopharmaceutical sector. AmacaThera's forward-thinking approaches and the shared expertise with its global partner hold the promise of breakthroughs that could redefine patient care in the years to come. For further information, visit www.amacathera.com.